Enodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules
Backed by multiple Sec61 inhibitor families, proteomics and cryo-EM datasets, and machine learning-driven design, Enodia Therapeutics’ platform is the foundation of a new research collaboration and license agreement with Pfizer.